It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microglia and neuroinflammation play an important role in the development and progression of Alzheimer’s disease (AD). Inositol polyphosphate-5-phosphatase D (INPP5D/SHIP1) is a myeloid-expressed gene genetically-associated with AD. Through unbiased analyses of RNA and protein profiles in INPP5D-disrupted iPSC-derived human microglia, we find that reduction in INPP5D activity is associated with molecular profiles consistent with disrupted autophagy and inflammasome activation. These findings are validated through targeted pharmacological experiments which demonstrate that reduced INPP5D activity induces the formation of the NLRP3 inflammasome, cleavage of CASP1, and secretion of IL-1β and IL-18. Further, in-depth analyses of human brain tissue across hundreds of individuals using a multi-analytic approach provides evidence that a reduction in function of INPP5D in microglia results in inflammasome activation in AD. These findings provide insights into the molecular mechanisms underlying microglia-mediated processes in AD and highlight the inflammasome as a potential therapeutic target for modulating INPP5D-mediated vulnerability to AD.
INPP5D/SHIP1 is a microglial-expressed gene that has been associated with Alzheimer’s disease through genetic studies. This study reveals that reduction in INPP5D activity induces activation of the NLRP3-inflammasome in human microglia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Department of Neurology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
2 Columbia University Irving Medical Center, Center for Translational and Computational Neuroimmunology, Department of Neurology, and the Taub Institute for the Study of Alzheimer’s Disease and the Aging Brain, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
3 Emory School of Medicine, Department of Biochemistry, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
4 Rush University Medical Center, Rush Alzheimer’s Disease Center, Chicago, USA (GRID:grid.240684.c) (ISNI:0000 0001 0705 3621)
5 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Department of Neurology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Harvard University, Harvard Stem Cell Institute, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)